BioLight Life Sciences Ltd. is a leading company investing in companies and managing projects relating to eye disease and their treatment. BioLight’s portfolio companies engage in advanced medical devices, medication, diagnostics and digital medicine and all exemplify the enormous potential of Israeli innovation in these fields.
Development and commercialization of the company’s ophthalmic technologies and products
The ophthalmic products developed by the companies in the BioLight group are aimed at innovative diagnosis and treatments for the needs of patient groups suffering from eye diseases. The different ophthalmic products are in various commercialization and clinical (or pre-clinical) phases.
BioLight intends, in line with its financial capabilities, to continue supplementing and expanding the array of technologies and products under development, whether through investment in additional companies or through business development and expansion of the activity of the existing companies.
Developments in Ophthalmology
Population growth and aging worldwide, as well as the increase in factors harming eye health (UV exposure, computer screens etc.) increase the need for innovative and effective solutions for eye diseases. Another factor is the downward trend in the number of ophthalmologists per capita and the need to reduce and streamline ophthalmology clinic visits, that has intensified during the Covid-19 pandemic.
Activity in Ophthalmology
BioLight’s ophthalmology activity includes research and development, investments and/or sales of the following ocular products:
DiagnosTear’s TeaRx™ technology is a diagnostic platform intended for diagnosis of disease in the frontal areas of the eye through examination of a number of substances in the composition of teardrops. The first indication is for identification, personal matching and monitoring of dry eye syndrome (DES).
ViSci’s Eye-D technology – development of a subconjunctival implant for the delayed and controlled release of an active substance for treating glaucoma, based on technology for which ViSci has received an exclusive worldwide license.
LipiCare Pharmaceuticals – development and commercialization activities for LipiCare, a range of eyedrop formulations for applying fatty molecule-based treatments to the ocular surface for a number of diseases and syndromes. LipiCare is engaged in its first product based on this technology, the Ocular D.
LIPITEAR™ – marketing of an approved medical product for the treatment of dry eye syndrome (DES) and for other eye disease uses.
OphRx – development of drugs for the treatment of eye diseases using an innovative technological platform to enhance the flow of eyedrops and substances injected into the eyes based on nanostructures.
IOPtiMate™ system from IOPtima is a medical device based on CO2 laser technology allowing surgery to be performed for the treatment of glaucoma without penetrating the interior of the eyeball in a process known as CLASS.
Additional ophthalmic technologies (through affiliates companies) from the portfolio of eye disease technologies and products in which BioLight has invested, include: Sanoculis, Belkin Laser, Tarsier Pharma and Aeye Health, Inc.
BioLight was incorporated in Israel and is a public company traded on the Tel Aviv Stock Exchange (TASE: BOLT).